A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itself, in combination with cetuximab, or in combination with KQB198? * Does KQB365 alone, in combination with cetuximab, or in combination with KQB198 decrease the size of the tumor? * What happens to KQB365 in the body? Participants will: * Receive KQB365 infusion weekly alone, in combination with cetuximab, or in combination with oral KQB198. * Visit the cli

Trial Details

NCT ID
NCT06720987
Phase
PHASE1
Sponsor
Kumquat Biosciences Inc.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • KQB365
  • Cetuximab
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Denver, Colorado, United States|39.73915,-104.9847
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Grand Rapids, Michigan, United States|42.96336,-85.66809

Key Eligibility Criteria

  • PART 1 (monotherapy and combo therapy with KQB198): Histologically confirmed diagnosis of a solid tumor malignancy with either a KRAS G12C or KRAS …
  • PART 1 (combo therapy with Cetuximab) \& PART 2: Histologically confirmed diagnosis of adenocarcinoma of the colon or rectum with either a KRAS G12…
  • Unresectable or metastatic disease
  • No available treatment with curative intent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →